These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 8918625)
1. Safety of intravenous injection of iron saccharate in haemodialysis patients. Sunder-Plassmann G; Hörl WH Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625 [TBL] [Abstract][Full Text] [Related]
2. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Parkkinen J; von Bonsdorff L; Peltonen S; Grönhagen-Riska C; Rosenlöf K Nephrol Dial Transplant; 2000 Nov; 15(11):1827-34. PubMed ID: 11071973 [TBL] [Abstract][Full Text] [Related]
3. Importance of iron supply for erythropoietin therapy. Sunder-Plassmann G; Hörl WH Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170 [TBL] [Abstract][Full Text] [Related]
4. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097 [TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
6. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901 [TBL] [Abstract][Full Text] [Related]
7. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [TBL] [Abstract][Full Text] [Related]
8. Intravenous iron supplementation in children on hemodialysis. Leijn E; Monnens LA; Cornelissen EA J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964 [TBL] [Abstract][Full Text] [Related]
9. The efficiency of fractionated parenteral iron treatment in CAPD patients. Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661 [TBL] [Abstract][Full Text] [Related]
10. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263 [TBL] [Abstract][Full Text] [Related]
11. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348 [TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
13. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC; Hung SC; Tarng DC Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299 [TBL] [Abstract][Full Text] [Related]
14. Monitoring iron status in end-stage renal disease patients on hemodialysis. Rafi A; Karkar A; Abdelrahman M Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895 [TBL] [Abstract][Full Text] [Related]
15. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467 [TBL] [Abstract][Full Text] [Related]
16. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430 [TBL] [Abstract][Full Text] [Related]
17. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647 [TBL] [Abstract][Full Text] [Related]
18. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE; Peat N; Porter C; Morgan AG Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972 [TBL] [Abstract][Full Text] [Related]
19. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Mars RL; Moles K; Pope K; Hargrove P Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Ahsan N; Groff JA; Waybill MA Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]